BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 20227326)

  • 1. United virus: the oncolytic tag-team against cancer!
    Le Boeuf F; Bell JC
    Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vesicular stomatitis virus in the fight against cancer].
    Janelle V; Poliquin L; Lamarre A
    Med Sci (Paris); 2013 Feb; 29(2):175-82. PubMed ID: 23452604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus combinations and chemotherapy for the treatment of human cancers.
    Kumar S; Gao L; Yeagy B; Reid T
    Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oncolytic viruses: riding high on the next wave?
    Stanford MM; Bell JC; Vähä-Koskela MJ
    Cytokine Growth Factor Rev; 2010; 21(2-3):177-83. PubMed ID: 20219409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virotherapy of breast cancer.
    Hartkopf AD; Fehm T; Wallwiener D; Lauer UM
    Gynecol Oncol; 2011 Oct; 123(1):164-71. PubMed ID: 21764108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of tumour cells for delivering oncolytic viruses.
    Raykov Z; Rommelaere J
    Gene Ther; 2008 May; 15(10):704-10. PubMed ID: 18356816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation oncolytic vaccinia vectors.
    Thorne SH
    Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of virotherapy for effective tumor treatment.
    Garcia-Aragoncillo E; Hernandez-Alcoceba R
    Curr Opin Mol Ther; 2010 Aug; 12(4):403-11. PubMed ID: 20677091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular stomatitis virus: re-inventing the bullet.
    Lichty BD; Power AT; Stojdl DF; Bell JC
    Trends Mol Med; 2004 May; 10(5):210-6. PubMed ID: 15121047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between oncolytic viruses augments tumor killing.
    Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
    Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
    Merrick AE; Ilett EJ; Melcher AA
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncolytic virus therapy using vesicular stomatitis virus].
    Ebert O
    Dtsch Med Wochenschr; 2009 Oct; 134(44):2236-8. PubMed ID: 19847736
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
    J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in oncolytic viral therapy.
    Woo Y; Adusumilli PS; Fong Y
    Curr Opin Investig Drugs; 2006 Jun; 7(6):549-59. PubMed ID: 16784026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of oncolytic measles virus: promises and challenges.
    Galanis E
    Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
    Nguyen TL; Wilson MG; Hiscott J
    Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
    Thorne SH; Contag CH
    Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.